#Dr Reddy’s Laboratories

[health4beauties]

Dr Reddys Laboratories | Inter Pass తో ఫార్మా కంపెని పర్మనెంట్ జాబ్స్ |F...

[pharmaapimanufacturer]

世界のトップAPIメーカーおよびサプライヤー企業から、GTIの下にあるOral Solid/CapsulesおよびSmall moleculeを使用してEtrasimod API（CAS No. 1200452-31-1）の見積もりをオンラインで入手してください。

[soniez]

India's Pharma Industry – The Leading Companies You Need to Know

India's pharmaceutical industry stands as a global powerhouse, contributing significantly to the world's supply of medicines and pharmaceutical products.  The country's ability to produce high-quality, affordable medicines has earned it the title of "Pharmacy of the World."  As the industry continues to grow and innovate, several companies have emerged as leaders in the market.  For Centurion HealthCare Pvt. Ltd., understanding the landscape of the top pharma companies in India provides insights into the key players driving the industry's success.

The Rise of the Pharmaceutical Industry in India

The pharmaceutical industry in India has seen exponential growth over the past few decades.  From generic drug manufacturing to complex biotechnological innovations, Indian pharma companies have made substantial contributions to global healthcare.  This growth can be attributed to several factors, including a skilled workforce, robust research and development infrastructure, and supportive government policies.

Key Players in India's Pharma Industry

The landscape of the pharmaceutical industry in India is populated by numerous companies, each contributing to various segments of the market.  Here are some of the top pharmaceutical companies in India that are leading the charge:

1.   Sun Pharmaceutical Industries Ltd.

As the largest pharmaceutical company in India, Sun Pharma is renowned for its diverse product portfolio, including generics, branded generics, specialty medicines, and active pharmaceutical ingredients (APIs).  The company has a significant global presence and continues to expand its footprint through strategic acquisitions and partnerships.

2.   Dr. Reddy's Laboratories

Dr. Reddy's is a major player in the global generic pharmaceutical market.  Known for its strong focus on research and development, the company offers a wide range of pharmaceuticals and biotechnology products.  Their commitment to quality and innovation has solidified their position as one of the best pharmaceutical companies in India.

3.   Cipla Ltd.

Cipla has been at the forefront of providing affordable medicines for over eight decades.  The company specializes in respiratory, cardiovascular, anti-retroviral, and anti-infective therapies.  Cipla's dedication to healthcare accessibility and its significant contributions to global health initiatives make it a top pharmaceutical company in India.

4.   Lupin Limited

Lupin is a leading pharmaceutical company known for its focus on complex generics and specialty drugs.  The company's strong presence in both developed and emerging markets has earned it a place among the top 10 pharmaceutical companies in India.  Lupin's investment in R&D and its broad therapeutic portfolio are key drivers of its success.

5.   Aurobindo Pharma

Aurobindo Pharma is recognized for its extensive range of generic formulations and APIs.  The company's robust manufacturing capabilities and strategic global presence have made it one of the top pharmaceutical companies in India.  Aurobindo's commitment to innovation and quality continues to propel its growth.

6.   Zydus Cadila

Zydus Cadila, a leading pharmaceutical company, offers a wide range of healthcare solutions, including small molecules, biologics, biosimilars, and vaccines.  The company's integrated operations and strong research capabilities have established it as a key player in the pharma industry in India.

7.   Glenmark Pharmaceuticals

Glenmark is a global research-led pharmaceutical company known for its focus on innovation in the fields of dermatology, respiratory, and oncology.  The company's strong pipeline of new chemical entities and biosimilars underscores its position as one of the best pharmaceutical companies in India.

8.   Torrent Pharmaceuticals

Torrent Pharma is a major player in the cardiovascular and central nervous system therapeutic areas.  The company's strategic acquisitions and focus on niche segments have helped it become one of the top pharmaceutical companies in India.  Torrent's commitment to quality and patient-centric approach is evident in its product offerings.

9.   Biocon Ltd.

Biocon is India's largest biopharmaceutical company, specializing in biologics and biosimilars.  The company's focus on affordable innovation and its significant contributions to chronic disease management make it a leader in the pharmaceutical industry in India.  Biocon's global partnerships and strong R&D capabilities are key to its success.

10. Cadila Healthcare (Zydus)

Cadila Healthcare, also known as Zydus, is a prominent player in the Indian pharma industry, offering a wide range of healthcare solutions.  The company's innovative approach and comprehensive product portfolio have positioned it among the top 10 pharmaceutical companies in India.

The Role of Pharma Manufacturing Companies in India

Pharma manufacturing companies in India play a crucial role in the global supply chain of medicines.  These companies not only produce high-quality generics but also invest heavily in research and development to bring new and innovative drugs to the market.  The efficiency and scale of Indian pharma manufacturing are key factors in the country's ability to provide affordable medicines worldwide.

Finding the Best Pharma Companies Near You

For those searching for "pharma companies near me," it's important to recognize the regional presence of leading pharmaceutical companies.  Many top pharma companies in India have established manufacturing and research facilities in various parts of the country, ensuring widespread access to their products and services.

Centurion HealthCare Pvt. Ltd.  – A Leading Player in the Industry

Centurion HealthCare Pvt. Ltd. is an emerging name in the Indian pharmaceutical landscape.  As a medicine manufacturing company in India, Centurion HealthCare is dedicated to providing high-quality pharmaceutical products across various therapeutic categories.  The company's commitment to innovation, quality, and patient care positions it among the best pharma companies in India.

The Future of the Pharmaceutical Industry in India

The future of the pharmaceutical industry in India looks promising, with continued growth driven by innovation, increasing healthcare needs, and expanding global reach.  Indian pharma companies are expected to play a pivotal role in addressing global health challenges, developing new treatments, and ensuring the availability of affordable medicines.

Conclusion

India's pharmaceutical industry is a dynamic and rapidly evolving sector, with numerous companies leading the way in innovation, quality, and global healthcare contributions.  From established giants like Sun Pharma and Dr. Reddy's to emerging leaders like Centurion HealthCare Pvt. Ltd., the top pharmaceutical companies in India are making significant strides in improving healthcare outcomes worldwide.

As the industry continues to grow, these companies will remain at the forefront of pharmaceutical advancements, ensuring that India retains its position as a global leader in medicine production and innovation.  Whether you are looking for the best pharma company in India or seeking reliable pharmaceutical companies in India, the landscape is rich with options that exemplify excellence and commitment to health.

For Centurion HealthCare Pvt. Ltd., being part of this esteemed group of pharma companies in India is a testament to its dedication to quality, innovation, and patient care.  As the industry moves forward, Centurion HealthCare is poised to continue its growth and contribute to the global healthcare landscape, solidifying its place among the best pharmaceutical companies in India.

[ibeforg]

India is home to some of the biggest pharmaceutical companies in the world, and our list of the top 10 pharma companies in India includes names like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Lupin Limited. These pharmaceutical companies in India are known for their innovative products, high-quality standards, and commitment to improving global healthcare. To get more information on pharmaceutical companies in india, visit the India Brand Equity Foundation website.

[thezeusos]

US FDA has no adverse observations after scan of Dr Reddy's Hyderabad R&D unit

Bringing news,sports,entertainment Drug makers Dr Reddy’s Laboratories Ltd (DRL) on Friday (September 20) said the United States Food & Drug Administration (FDA) has completed a routine Good Manufacturing Practice (GMP) inspection at its integrated product development organisation (IPDO) in Bachupally, Hyderabad. This is to inform you that the United States Food & Drug Administration (USFDA)…

[manostaxx]

Top 10 Generic Companies in the World - 7 are India Based

Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr. Reddy’s Laboratories Ltd, and Lupin Ltd are the top 5 Global Generic Companies in 2021 by revenue. Cumulatively, the top 10 Global Generic Companies generated revenue of $37,454 million, with average revenue growth of 6.97%, the highest revenue was generated by Teva Pharmaceutical Industries Ltd ($16,659…

[idataacumen]

Plerixafor Injection Market Outlook, Trends And Future Opportunities (2024-2031)

Plerixafor Injection Market is growing at a CAGR of 7.2% over the next 5 years. Genzyme Corporation, Sanofi S.A, Cadila Healthcare, Mylan N.V., IDsA Generics, Cipla Ltd., Sun Pharmaceutical, Dr. Reddy’s Laboratories Ltd., Accord Healthcare, Natco Pharma, Biocon Ltd., Intas Pharmaceuticals, Pfizer Inc. are the major companies operating in Plerixafor Injection Market

Plerixafor Injection Market Outlook

[colinwilson11]

The Rising Super Generics Market Driven By Increased Accessibility Of Affordable Medicines

Super generics are generic pharmaceutical drugs that are therapeutically equivalent to brand-name drugs but are significantly cheaper than both branded and ordinary generics. Super generics help overcome price barriers for patients living with chronic diseases by offering high-quality medicines at a fraction of brand-name drug costs. They are developed through a complex process involving developing robust generic drug applications with focus on matching active ingredients and treatment efficacy of reference drugs. The Super Generics Market is driven by the need to enhance access to medicines for a broader patient base while controlling increasing healthcare costs.

Key Takeaways

The Super Generics Marketis estimated to be valued at US$ 84 Bn in 2024 and is expected to exhibit a CAGR of 8.3% over the forecast period 2024-2031.

Key players operating in the super generics market are Accord Healthcare, Alcon Laboratories, Azurity Pharmaceuticals, Baxter, and Dr. Reddy’s Laboratories. These companies are focusing on expanding their generics drug portfolios and enhancing manufacturing scale to tap the high-growth super generics market segment.

The rising prevalence of chronic diseases and increasing healthcare costs are driving robust demand for more affordable generic drugs. Super generics are being preferred over ordinary generics as they provide nearly equivalent efficacy at 60-70% lower costs than reference drugs.

Technological advancements are helping super generics players develop robust generic equivalents of complex drugs and molecules. This is expanding treatment access in disease areas that were previously addressed only through expensive brand medications. Continuous innovations will remain crucial for market leadership.

Market Trends

Increasing approvals for complex generics - Regulatory agencies are promoting faster approvals for generic versions of complex drugs treating conditions like cancer, hepatitis C, and multiple sclerosis. This will significantly boost the super generics market.

Focus on specialty drug segments - Major players are developing robust portfolios targeting specialty drug categories like oncology, CNS disorders, and autoimmune diseases that dominate the prescription landscape. This represents a massive opportunity.

Market Opportunities

Opening of emerging markets - Markets in Latin America, Middle East, Africa, and Asia still rely majorly on on-patent branded drugs due lack of alternatives. increased super generics access can transform healthcare in these regions.

Partnerships for difficult-to-copy drugs - Companies are tying up with specialized players for technologies and know-how to develop low-cost versions of biologics and other difficult drugs, presenting a long growth runway.

Impact Of COVID-19 On Super Generics Market Growth

The COVID-19 pandemic has adversely impacted the super generics market growth. During the peak of the pandemic in 2020-2021, many manufacturing facilities were shut down momentarily due to lockdowns imposed by various governments. This led to disrupted supply chains and shortage of APIs (Active Pharmaceutical Ingredients). Many generics drug formulations also faced shortage issues. The demand for life-saving generics drugs saw a sharp rise during the pandemic. However, the supply could not keep up with such heightened demand levels. This mismatch negatively impacted the market revenues during these periods.

As the pandemic situation gradually stabilizes with declining infection rates worldwide, the super generics market is expected to bounce back strongly. The overall demand for affordable generics drugs remains high. Many new products are also in the pipeline for launch post-COVID. With resumption of normal operations across manufacturing facilities, the supply chains are getting restored. The easy availability of generics drugs will be crucial for universal healthcare during the post-COVID era. The market is anticipated to demonstrate accelerated growth trajectory from 2022 onwards to makeup for the pandemic disruptions.

Geographical Regions With Highest Value Concentration In Super Generics Market

North America accounts for the largest share of the Super Generics Market in terms of value. The U.S. market contributes significantly to the high revenue generation from the region. Low drug prices and patent expirations in the U.S. provide lucrative opportunities for super generics companies. Europe is another leading regional market, driven by favorable pricing policies and high acceptance of generics drugs across major countries like Germany, France, U.K, Spain, and Italy.

Fastest Growing Regional Market For Super Generics

Asia Pacific region is poised to showcase the fastest growth in the Super Generics Market over the forecast period from 2024 to 2031. The expanding patient population, rising healthcare spending, and ongoing initiatives to enhance healthcare access are fueling the market demand in Asia Pacific economies such as India, China, Australia, Japan, and South Korea. Significant investments by international generics drug makers to tap opportunities in the growth markets of Asia Pacific will further support the region’s growth momentum.

Get more insights on this topic:  https://www.trendingwebwire.com/the-super-generics-market-set-for-growth-due-to-advancements-in-bioavailability-enhancement-technologies/

 

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )

 

What Are The Key Data Covered In This Super Generics Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Super Generics Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Super Generics Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Super Generics Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Super Generics Market vendors

FAQ’s

Q.1 What are the main factors influencing the Super Generics Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Super Generics Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Super Generics Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[sudheervanguri]

Dr. Reddy's Laboratories, a global leader in pharmaceutical manufacturing, is seeking a qualified Clinical Research Associate for its Hyderabad location. This role requires a master's degree in pharmacy or life sciences and 2-5 years of research experience. Join a dynamic team committed to advancing healthcare through innovative clinical trials. Job Description Job Summary We are looking for an experienced Clinical Research Associate to join our team in Hyderabad. This role involves processing, reviewing, and receiving clinical data from therapeutic groups, internal and external investigators, and ensuring accurate and timely data delivery to clinical teams. Roles & Responsibilities Facilitate Study Start up activities at Clinical Investigational Site Conduct Feasibility & assess the data Conduct site qualification visits to assess suitability of sites for study conduct including review of Investigator qualifications, site staff adequacy, site facilities, patient pool & share feedback to project team Collection of essential documents including validation records for site equipment from selected sites for regulatory and EC submissions Identify the training needs for the site to perform adequate conduct of trial Ensure supply of clinical trial material to sites before study initiation End to End clinical investigational site management: Initiate the study at clinical investigational sites Provide study protocol and related trainings Perform review of Informed Consent forms and narrative Perform review of source records, perform SDV Review of CRF data entry, data queries and coordinate with sites to resolve Ensure timely completion and review of site visit reports and addressing action items via follow up letters, tracking of action items till closure IP accountability and reconciliation Ensure adequate initial supply & re-supply of IP per study plan to clinical trial sites Provide adequate oversight to IP collection, storage, temperature monitoring including review of log, administration to study subjects Identification of any temperature excursions and suitability of IP for subject administration Ensure destruction of expired / used IP on site or return of such IP back to local depot, per study requirement & adequate documentation for same. Review of completion of logs, filing of relevant shipment etc. documentation in site / pharmacy file. Site Contracts and Site Payment Coordination Coordinate for CDA, Clinical trial agreements review and finalization and amendments, as applicable Ensure that site invoices are being generated as per clinical trial agreement Review and approval of site invoices and submission to payment processing team Coordinate for the payment release & confirm for site acknowledgements Perform ongoing reconciliation of payments against site activities including subject visits conduct etc. Liaising with safety lab for timely samples receipt, processing and release of reports & identify, resolve any issues / risks around same. Ensure that the Bio-analytical samples are stored as per storage conditions mentioned in the lab manual including reconciliation and query resolution Liaising with other vendors and help sites in any query resolutions for vendor related activities Liaising with internal project teams including but limited to Data Management for EDC issues, data queries and reconciliations, Safety team for SAE related issues, Medical team for any protocol / eligibility related queries etc. Liaising with Internal & External Stakeholders Ensuring Compliance to Protocol & Applicable study plans, SOPs, GCP and regulatory requirements Ensure compliance to Protocol Ensure compliance to study plans, applicable SOPs and related regulatory requirements Ensure compliance to ICH GCP Ensure compliance to good documentation practices including ALCOA-C Identification of significant deviations to protocol / plans / procedures, escalation to project lead

/ clinical ops lead and propose adequate mitigation plans / CAPA, Review of implementation of CAPA / mitigation plans, identify need for training and provide training / re-training in case of any changes Support audits, inspections / QC visits, as required per study plans Trial Master File Review and Maintenance for Inspection Readiness Ensure that sites are timely updating the documents in Investigator site file Retrieval of essential documents from sites for In house filing / Central files Review of onsite and in house files at defined frequency per monitoring / TMF plan for study Ensure adequacy of TMF for all time inspection readiness [caption id="attachment_90685" align="aligncenter" width="1200"] Dr. Reddy's Laboratories Hiring Clinical Research Associate Hyderabad[/caption] Qualifications Educational Qualification: Master's degree in pharmacy, life sciences, biology, biotechnology, or biochemistry, or a diploma in clinical research. Work Experience: 2-5 years of research experience. Technical Skills: Proficiency in clinical trial operations, market research, regulatory guidelines (GCP, ICH), medical terminology, and EDC systems. Behavioral Skills: Excellent communication, negotiation, and interpersonal skills, strong project management and analytical abilities, and a results-oriented mindset. How to Apply Interested candidates can apply via LinkedIn.

[pharmaapimanufacturer]

Obtenha uma cotação de Edaravone API (CAS No. 89-25-8) com Injetável e Sintético em Sistema Nervoso Central (SNC) on -line da principal empresa global de API e empresa de fornecedores.

[creativeera]

The Generic Sterile Injectables Market poised for strong growth driven by increasing demand for affordable healthcare

The generic sterile injectables market encompasses pharmaceutical formulations such as vials, ampoules, bottles, syringes and bags, which are administered parenterally into the body for treatments. They offer effective and affordable alternatives to branded sterile injectable drugs across therapeutic areas including oncology, cardiovascular diseases, infectious diseases and autoimmune diseases. The growing prevalence of chronic diseases and increasing healthcare expenditure have boosted the demand for generic sterile injectables globally.

The global generic sterile injectables market is estimated to be valued at US$ 46.33 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the generic sterile injectables market are Baxter International Inc., AstraZeneca plc, Merck and Co., Inc., Pfizer Inc., Fresenius Kabi, Novartis International AG, Teva Pharmaceuticals, Hikma Pharmaceuticals, Dr. Reddy's Laboratory, Mylan N.V., Sun Pharmaceutical Industries Ltd. The key players dominate the market with their wide array of products in various dosages. The increasing prevalence of chronic diseases and aging population has amplified the demand for affordable healthcare solutions. The rising healthcare costs have prompted patients and providers to shift towards cost-effective generic injectable drugs from branded equivalents. This has accelerated the growth of the global generic sterile injectables market. With rising healthcare expenditures, healthcare providers are boosting investments in emerging markets of Asia Pacific, Latin America, Middle East and Africa for expansion of their generic sterile injectables portfolio. Generic Sterile Injectables Market Trends is expected to drive during the forecast period. Market Key Trends Increased Research & Development and manufacturing capabilities of emerging players: With growing demand for affordable and effective biologics, emerging players are investing significantly in R&D and expanding their sterile injectables manufacturing infrastructure. This has led to increased competition and entry of more affordable biologics in the market.

Porter’s Analysis Threat of new entrants: Low barriers to entry make it easy for new companies to enter the market. However, regulations and requirement of high capital to set-up sterile facilities pose challenges. Bargaining power of buyers: Large group purchasing organizations and hospital networks have significant influence on prices. However, need for essential medicines keeps bargaining power in check. Bargaining power of suppliers: Few major global players supply key starting materials and APIs. However, potential for forward integration limits suppliers' bargaining power. Threat of new substitutes: Limited threat as generics have few major therapeutic substitutes. Biosimilars pose a potential long-term threat in certain disease segments. Competitive rivalry: Intense competition on pricing and new product development. Major players compete by improving quality, reliability of supply and enhancing portfolios. Frequent litigation and regulatory issues also impact competition. The United States dominates the Generic Sterile Injectables Market Regional Analysis accounting for over 40% revenue share in 2024. Strong payer system, sizable healthcare spending and increasing generic adoption to contain costs drive high growth. China sterile injectables market is projected to grow at over 12% till 2031, making it the fastest growing regional market. This can be attributed to rising living standards, healthcare reforms focusing on essential medicines and initiatives to expand domestic sterile manufacturing capabilities.

Get more insights on Generic Sterile Injectables Market

Get More Insights—Access the Report in the Language that Resonates with You

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )

[xnewsinfo]

China's Nationwide Medical Merchandise Administration (NMPA) has suspended the import, sale and use of drugmaker Dr. Reddy's Laboratories' atomoxetine hydrochloride capsules from August 30, 2024. The motion was taken following a distant inspection of the corporate’s formulation manufacturing facility (FTO-3 in Bachupally, Hyderabad) for atomoxetine hydrochloride capsules performed not too long ago by the NMPA. The inspection concluded that the standard administration of the manufacturing of atomoxetine hydrochloride capsules doesn't adjust to the necessities of China’s “Good Manufacturing Practices for Medicines”. [Revised in 2010]"Dr. Reddy stated in a presentation on Saturday.Because of the NMPA's motion, China's Nationwide Joint Drug Procurement Workplace (NDJPO) determined to cancel the "winner" standing of Dr. Reddy's Atomoxetine Hydrochloride Capsules and embrace the corporate within the "violation checklist", thereby suspending the corporate's eligibility to take part in nationwide centralized drug procurement actions from August 30, 2024 to February 28, 2026. Atomoxetine hydrochloride capsules are used within the remedy of consideration deficit hyperactivity dysfunction (ADHD). Dr. Reddy's stated it's within the strategy of figuring out the financial impression of the orders. On Monday, the corporate's shares closed 2.26% decrease at ₹6,870.35 apiece on the Boston Inventory Trade. The corporate is reported to have been made conscious of orders dated August 30, 2024 from the Nationwide Medical Merchandise Administration of China and the Nationwide Joint Procurement Workplace of China, made out there via its web site.

[optionperks]

Top Gainers and Losers today on 2 September, 2024: Bajaj Finance, Bajaj Finserv, Hindalco Industries, Dr Reddys Laboratories among most active stocks

Top Gainers and Losers Today : The Top Gainers and Losers Today: The Nifty closed at 25,235.9, up by 0.17%. During the day, the Nifty touched a high of 25,333.65 and a low of 25,235.5. The Sensex traded in the range of 82,725.28 and 82,440.93 and closed 0.24% up at 82,365.77, which was 194.07 points above the opening price. The Midcap index underperformed the Nifty 50 as the Nifty Midcap 50 closed 0.18% down. Small cap stocks also underperformed the Nifty 50, with the Nifty Small Cap 100 ending at 19,307.1, down by 62.8 points and 0.33% lower.

Nifty Index Top Gainers and Losers Today The top gainers in the Nifty index were Bajaj Finance (up 3.33%), Bajaj Finserv (up 3.22%), HCL Technologies (up 3.05%), Hero Motocorp (up 2.25%), and Bajaj Auto (up 2.15%). The top losers in the Nifty index were Hindalco Industries (down 2.49%), Dr. Reddy's Laboratories (down 2.26%), Tata Motors (down 1.68%), NTPC (down 1.49%), and Oil & Natural Gas Corporation (down 1.38%).

Sensex: Top Gainers: Bajaj Finserv (up 3.23%), Bajaj Finance (up 3.19%), HCL Technologies (up 3.13%), ITC (up 1.60%), Indusind Bank (up 1.55%)

Top Losers: NTPC (down 1.57%), Tata Motors (down 1.52%), Wipro (down 1.12%), Mahindra & Mahindra (down 1.04%), Bharti Airtel (down 0.97%)

Nifty: Top Gainers: Bajaj Finance (up 3.33%), Bajaj Finserv (up 3.22%), HCL Technologies (up 3.05%), Hero Motocorp (up 2.25%), Bajaj Auto (up 2.15%)

Top Losers: Hindalco Industries (down 2.49%), Dr. Reddy's Laboratories (down 2.26%), Tata Motors (down 1.68%), NTPC (down 1.49%), Oil & Natural Gas Corporation (down 1.38%)

[poonamcmi]

Bortezomib Market Estimated to Witness High Growth Owing to Rising Adoption of Proteasome Inhibitors

The bortezomib market is primarily driven by high incidence and prevalence of multiple myeloma across the globe. Bortezomib, which is commonly sold under the brand name Velcade among others, is a proteasome inhibitor primarily used for the treatment of multiple myeloma and mantle cell lymphoma.

The global proteasome inhibitor drug market size is valued at approximately US$ 24.54 million in 2024 and is expected to register a CAGR of 4.7% over the forecast period of 2024-2031. The introduction of novel proteasome inhibitors and their increasing adoption in the treatment of cancer are the major factors anticipated to propel market growth. Key Takeaways

Key players operating in the bortezomib market are Hikma Pharmaceuticals, Pfizer, Meitheal Pharmaceuticals, Novartis International AG, Bristol Myers Squibb, NATCO Pharma, Teva Pharmaceuticals, Dr. Reddy's Laboratories, Gland Pharma, Shilpa Medicare, Qilu Pharmaceutical, Scion Pharmaceuticals, Farmhispania Group, Coresyn, Chem-Stone (Guangzhou), Hubei Honch Pharmaceutical, Vinkem Labs, Icrom, TAPI Teva, and Chengdu Aslee Biopharmaceuticals.

The introduction of generic versions of Bortezomib Market Demand has led to increased adoption and lowered treatment costs. Moreover, ongoing clinical trials evaluating the efficacy of bortezomib in other cancer indications are expected to expand the eligible patient pool. Technological advancements in proteasome inhibitor development focused on overcoming resistance, reducing toxicity, and novel delivery systems are further anticipated to support market growth. Market Drivers

The primary factors driving the growth of the global bortezomib market include rising prevalence of multiple myeloma globally, increasing adoption of proteasome inhibitors in treatment regimens, availability of generic versions, and ongoing clinical research evaluating the efficacy of bortezomib in other cancer indications. Additionally, improving healthcare infrastructure and expenditures in emerging economies will further support the market growth during the forecast period. Current challenges in Bortezomib Market

The Bortezomib Market Size And Trends  faces several challenges primarily due to the presence of alternative therapeutic options for treating multiple myeloma (MM). Some of the major challenges include increasing generic competition from drugs like ixazomib and daratumumab which are leading to lower sales of bortezomib drugs. Further, the patents of bortezomib drugs have expired in several regions making them available in generic forms at lower costs. This increasing availability of low-cost generics is a major challenge faced by innovator bortezomib drug companies. Additionally, the adverse side effects associated with bortezomib drugs like neuropathy and thrombocytopenia require close patient monitoring during treatment posing operational challenges. Stringent regulations for drug approval is another regulatory challenge for new market entrants. SWOT Analysis

Strength: Well-established drug with proven efficacy and safety profile in treating MM. It was the first proteasome inhibitor approved and remains a standard of care. Weakness: Patent expiry has led to availability of low-cost generics reducing sales of innovator brands. Further, it causes serious side effects like neuropathy requiring cautious use. Opportunity: Emerging economies with growing cancer burden and healthcare spending present an opportunity. Combination therapies with other anti-MM drugs can boost its use further. Threats: Increasing competition from newer oral proteasome inhibitors and monoclonal antibody based therapies poses pricing and market share threats. Stringent regulations for approval delays market entry of new players.

Geographical regions with high market concentration

In terms of value, North America accounts for the largest share of over 40% of the global bortezomib market led by the US. This is due to established healthcare infrastructure and higher adoption of innovative therapies. Europe is the second major regional market with a value share of over 30% supported by favourable reimbursement policies. The Asia Pacific region is projected to be the fastest growing market during the forecast period due to rising healthcare expenditure, growing cancer incidence and increasing demand for cancer treatments from middle-income countries like China and India. Fastest growing geographical region

The Asia Pacific region is poised to exhibit the highest growth rate during the forecast period in the global bortezomib market. This is attributed to rising disposable incomes, growing awareness about cancer treatments, expansion of healthcare facilities and increasing private sector investment in pharmaceutical research in emerging economies like China and India. Large patient pools undergoing cancer treatment in Asia present lucrative opportunities for bortezomib drug makers looking to tap high future growth potential in this region. Get More Insights On, Bortezomib Market For More Insights Discover the Report In language that Resonates with you French, German, Italian, Russian, Chinese, Korean About Author: Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

[exim-pedia]

How to Export Medicines from India: A Comprehensive Guide

India stands as a prominent global player in the pharmaceutical industry, known for its extensive production and export of medicines. With its substantial contribution to the world's pharmaceutical needs, understanding how to export medicines from India can be both lucrative and impactful. This article provides a detailed overview of the process, requirements, and key insights into medicine exports from India.

1. Overview of India's Pharmaceutical Export Market

India is a major force in the global pharmaceutical market, contributing significantly to the production and supply of medicines. Here’s a snapshot of India’s pharmaceutical export landscape:

Global Leadership: India accounts for 20% of the world’s pharmaceutical volume and over 60% of global vaccine supply.

Export Growth: Pharmaceutical exports from India surged from Rs. 90,415 crore in 2013–14 to Rs. 2,04,110 crore in 2022–23, reflecting a remarkable growth trajectory.

Key Products: The primary products exported include formulations, biologics, bulk pharmaceuticals, and drug intermediates. Formulations and biologics alone make up approximately 73.31% of India’s pharmaceutical exports.

2. Major Medicines Exported from India

India’s pharmaceutical sector exports a wide range of medicines. Some of the most commonly exported medicines include:

Analgesics & Anti-Inflammatories

Antispasmodic Analgesics

Diuretics & Anti-Diuretics

Pro-Kinetics & Gut Relaxants

Anti-Asthmatics

Antibacterials

These medicines are essential in various therapeutic areas, including pain management, gastrointestinal health, respiratory issues, and bacterial infections.

3. Key Destinations for Indian Medicines

India’s pharmaceutical exports reach over 200 countries, with significant markets including:

United States: The largest importer, accounting for over 31% of India’s pharmaceutical exports.

South Africa

Belgium

United Kingdom

Brazil

India’s export markets also extend to the Middle East, Asia, CIS, North America, Africa, the European Union, ASEAN, Latin America, and the Caribbean.

4. Steps to Export Medicines from India

Exporting medicines from India involves several crucial steps:

Business Registration and Documentation:

Register Your Business: Ensure your business is registered with the Ministry of Corporate Affairs (MCA) and has GST registration.

Obtain an Import Export Code (IEC): Required for international trade.

Drug License: A license from the relevant Drug Regulatory Authority in India.

Certificate of Pharmaceutical Product (CPP): Required for international markets.

Product Compliance:

Get Approval from DCGI: Ensure your products meet the Drug Controller General of India’s standards.

Product Registration in Destination Country: Comply with the regulatory requirements of the importing country.

Logistics and Distribution:

Customs Clearance: Work with a customs agent to manage export documentation and compliance.

Find Distributors and Buyers: Establish connections with international distributors or buyers.

Export Documentation:

Certificate of Analysis

Letter of Credit (if applicable)

Proforma Invoice

Destination Control Statement

5. Key Export Data and Trends

2021–2022: India’s pharmaceutical exports amounted to US$ 24.62 billion, with a 1% increase from the previous year.

2022–2023: The total value of pharmaceutical exports reached US$ 25.4 billion.

Growth Rate: The export value grew by 18% year-on-year from 2020–21 to 2021–2022.

Formulations and biologics dominated the export market, representing about 75% of total pharmaceutical exports.

6. Leading Pharmaceutical Exporters in India

Some of the prominent medicine exporters in India include:

Elkos Healthcare Pvt. Ltd.

Aurobindo Pharma

Cipla Limited

Dr. Reddy’s Laboratories

Sun Pharmaceutical Industries

Lupin Limited

These companies have established themselves as significant contributors to the global pharmaceutical supply chain.

7. Why is India Famous for Medicine?

India’s prominence in the pharmaceutical industry is attributed to:

Affordable and High-Quality Medications: India is often referred to as the "Pharmacy of the World" due to its ability to produce cost-effective medicines.

Medical Tourism: India is a leading destination for medical tourism, offering advanced medical care at lower costs compared to many Western countries.

Rich Heritage in Ayurveda: India’s traditional medical system, Ayurveda, continues to be a significant aspect of its pharmaceutical offerings, particularly in the export of herbal and traditional medicines.

8. Conclusion

Exporting medicines from India involves a structured process, including obtaining the necessary licenses, complying with international regulations, and navigating logistics. With its strong position in the global pharmaceutical market, India offers substantial opportunities for businesses in the medicine export sector. By understanding the market dynamics and adhering to the required steps, businesses can successfully engage in pharmaceutical exports.

For detailed and up-to-date export data and to connect with medicine exporters, platforms like Eximpedia.app provide valuable insights and resources.

FAQs

Who is the largest exporter of medicine in India?

Elkos Healthcare Pvt. Ltd. is considered the largest exporter, alongside other significant players like Aurobindo Pharma and Cipla Limited.

What medicines are exported from India?

Major exports include analgesics, anti-inflammatories, diuretics, and antibacterials.

How to start pharma export?

Understand market dynamics, obtain necessary documentation, and comply with regulatory requirements.

Which countries buy medicine from India?

Major importers include the United States, South Africa, Belgium, the UK, and Brazil.

How many documents are required for pharma export?

Required documents include business registration, drug license, IEC, CPP, and more.

Why is India famous for medicine?

India is known for its affordable medications, rich Ayurvedic heritage, and robust pharmaceutical sector.

For more information on Ayurvedic medicine export from India or other related queries, contact Eximpedia.app for the latest global trade data and insights.